Therefore, this study contributes to a better understanding of the molecular mechanisms underlying the pathogenesis of CAVD and highlights the potential of targeting the OxPL-ATF4 axis as a therapeutic strategy for the treatment of this disease. Here, ATF4 is linked to congenital bilateral aplasia of vas deferens from CFTR mutation.